Generations of stents in the treatment of ischemic cardiopathy
DOI:
https://doi.org/10.33448/rsd-v9i9.7049Keywords:
Drug-eluting stents; Percutaneous coronary intervention; Comparative study.Abstract
Coronary Artery Disease predisposes to the development of ischemic heart disease, being one of the main causes of morbidity and mortality worldwide. Percutaneous coronary interventions revascularize the myocardium through the implantation of stents in order to restore blood flow in the affected arteries. Due to the high use of these devices in percutaneous procedures, as well as the currently found limitations, such as stent thrombosis, restenosis and adverse cardiac events, the aim of the present study was to analyze publications that deal with the different generations of stents in the treatment of arterial disease coronary, through a literary review, with a search in Scielo, Pubmed and Sciencedirect databases. Drug-eluting stents have emerged as a safer and more effective alternative than conventional stents, reducing episodes of restenosis and major adverse cardiac events. However, an increased risk of thrombosis linked to its use was observed. Thus, by improving the design, as well as the materials used in its manufacture, several generations of drug-eluting stents were developed, expanding the therapeutic collection. Despite this, further studies are still needed to prove its long-term safety.
References
Akinapelli, A., Chen, J. P., Roy, K., Donnelly, J., Dawkins, K., Huibregtse, B., & Hou, D. (2017). Current State of Bioabsorbable Polymer-Coated Drug-Eluting Stents. Current Cardiology Reviews, 13(2), 139–154.
Alam, S. T., Ansari, A. Q., Urooj, S., & Aldobali, M. (2019). A Review based on Biodegradable and Bioabsorbable Stents for Coronary Artery Disease. In: Gupta, N., Grover, N. R., Piuri, V., Balas, V. A., & Liu, C. M. Procedia Computer Science, 354-359. Amsterdam: Elsevier.
Bonaa, K. H., Mannsverk, J., Wiseth, R., Aaberge, L., Myreng, Y., Nygård, O., Nilsen, D. W., Kløw, N. E., Uchto, M., Trovik, T., Bendz, B., Stavnes, S., Bjørnerheim, R., Larsen, A. I., Slette, M., Steigen, T., Jakobsen, O. J., Bleie, O., Fossum, E., Hanssen, T. A. Norstent Investigators. (2016). Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease. The New England journal Of Medicine, 375(13), 1242–1252.
Borhani, S., Hassanajili, S., Ahmadi Tafti, S. H., & Rabbani, S. (2018). Cardiovascular stents: overview, evolution, and next generation. Progress In Biomaterials, 7(3), 175–205.
Bowen, P. K., Shearier, E. R., Zhao, S., Guillory, R. J., Zhao, F., Goldman, J., & Drelich, J. W. (2016). Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys. Advanced Healthcare Materials, 5(10), 1121–1140.
Buccheri, S., & Capodanno, D. (2019). Bioabsorbable stents: only bad news?. European heart journal supplements: journal of the European Society of Cardiology, 21(Suppl B), B28–B30.
Canfield, J., & Totary-Jain, H. (2018). 40 Years of Percutaneous Coronary Intervention: History and Future Directions. Journal Of Personalized Medicine, 8(4), 33.
Chhabra, L.; Zain, M. A., & Siddiqui, W. J. Coronary Stents. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing.
Colmenares, G., Agudelo, L., Quintero, Y., e Hoyos, L. (2017). Evolução dos stents coronarianos farmacológicos, da primeira à quarta geração. CES Medicine, 31 (2), 163-171.
Dalal A. (2016). Organ transplantation and drug eluting stents: Perioperative challenges. World Journal Of Transplantation, 6(4), 620–631.
De Luca, G., Smits, P., Hofma, S. H., Di Lorenzo, E., Vlachojannis, G. J., Van't Hof, A., van Boven, A. J., Kedhi, E., Stone, G. W., Suryapranata, H., & Drug-Eluting Stent in Primary Angioplasty (DESERT 3) cooperation (2017). Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials. International Journal Of Cardiology, 244, 121–127.
De Pommereau, A., de Hemptinne, Q., Varenne, O., & Picard, F. (2018). Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away?. Archives Of Cardiovascular Diseases, 111(4), 229–232.
El-Hayek, G., Bangalore, S., Casso Dominguez, A., Devireddy, C., Jaber, W., Kumar, G., Mavromatis, K., Tamis-Holland, J., & Samady, H. (2017). Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC. Cardiovascular Interventions, 10(5), 462–473.
Feinberg, J., Nielsen, E. E., Greenhalgh, J., Hounsome, J., Sethi, N. J., Safi, S., Gluud, C., & Jakobsen, J. C. (2017). Drug-eluting stents versus bare-metal stents for acute coronary syndrome. The Cochrane Database Of Systematic Reviews, 8(8), CD012481.
Fischell, T. A., Balmuri, A., Agarwal, S., & Verhye, S. (2020). Integrated Stent Delivery System: A Next Generation of Stent Delivery and Drug-Eluting Stent. Cardiovascular Revascularization Medicine: Including Molecular Interventions, 21(2), 205–212.
Guerra, A. J., Cano, P., Rabionet, M., Puig, T., & Ciurana, J. (2018). 3D-Printed PCL/PLA Composite Stents: Towards a New Solution to Cardiovascular Problems. Materials (Basel, Switzerland), 11(9), 1679.
Kereiakes, D. J., Ellis, S. G., Metzger, C., Caputo, R. P., Rizik, D. G., Teirstein, P. S., Litt, M. R., Kini, A., Kabour, A., Marx, S. O., Popma, J. J., McGreevy, R., Zhang, Z., Simonton, C., Stone, G. W., & ABSORB III Investigators (2017). 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial. Journal Of The American College Of Cardiology, 70(23), 2852–2862.
Kounis, N. G., Koniari, I., Roumeliotis, A., Tsigkas, G., Soufras, G., Grapsas, N., Davlouros, P., & Hahalis, G. (2017). Thrombotic responses to coronary stents, bioresorbable scaffolds and the Kounis hypersensitivity-associated acute thrombotic syndrome. Journal Of Thoracic Disease, 9(4), 1155–1164.
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine, 6(7), e1000100.
Mostaed, E., Sikora-Jasinska, M., Drelich, J. W., & Vedani, M. (2018). Zinc-based alloys for degradable vascular stent applications. Acta Biomaterialia, 71, 1–23.
Nakamura, K., Keating, J. H., & Edelman, E. R. (2016). Pathology of Endovascular Stents. Interventional Cardiology Clinics, 5(3), 391–403.
Nogic, J., McCormick, L. M., Francis, R., Nerlekar, N., Jaworski, C., West, N., & Brown, A. J. (2018). Novel bioabsorbable polymer and polymer-free metallic drug-eluting stents. Journal Of Cardiology, 71(5), 435–443.
Pereira A.S.; Shitsuka, D. M.; Parreira, F. J.; Shitsuka, R. (2018). Metodologia da pesquisa científica. In Colusso, P. R., Construção e validação de instrumentos e técnicas de coleta de dados (pp. 42-43). Santa Maria: UFSM, NTE.
Serruys, P. W., Chevalier, B., Sotomi, Y., Cequier, A., Carrié, D., Piek, J. J., Van Boven, A. J., Dominici, M., Dudek, D., McClean, D., Helqvist, S., Haude, M., Reith, S., de Sousa Almeida, M., Campo, G., Iñiguez, A., Sabaté, M., Windecker, S., & Onuma, Y. (2016). Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet (London, England), 388(10059), 2479–2491.
Shah P. K. (2019). Inflammation, infection and atherosclerosis. Trends In Cardiovascular Medicine, 29(8), 468–472.
Shi, H. T., Chu, H. X., Gu, W., Cai, X. Y., Guo, J. J., Ding, Z. G., Gao, W., Ma, L. L., Zhu, J. B., Liu, H. B., Huang, Z. Y., Wang, Q. B., Ge, J. B., & Wen, S. J. (2016). Second-generation versus first-generation drug-eluting stents in saphenous vein graftdisease: A meta-analysis of randomized controlled trials. International Journal Of Cardiology, 214, 393–397.
Silva, G. B. G., Junior, J. R. C., Sousa, A., Sousa, J. E., & Abzaid, A. Drug-eluting stents: state-of-the-art. (2018). Rev Soc Cardiol Estado de São Paulo, 28(1), 54-9.
Torrado, J., Buckley, L., Durán, A., Trujillo, P., Toldo, S., Valle Raleigh, J., Abbate, A., Biondi-Zoccai, G., & Guzmán, L. A. (2018). Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. Journal Of The American College Of Cardiology, 71(15), 1676–1695.
Wentzlaff, M., Senz, V., & Seidlitz, A. (2019). Evaluation of the suitability of a fluidized bed process for the coating of drug-eluting stents. European journal of pharmaceutics and biopharmaceutics: Verfahrenstechnik, e.V, 139, 85–92.
Wu, J. J., Way, J., Roy, P., Yong, A., Lowe, H., Kritharides, L., & Brieger, D. (2018). Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. Health Science Reports, 1(11), e93.
Wykrzykowska, J. J., Kraak, R. P., Hofma, S. H., van der Schaaf, R. J., Arkenbout, E. K., IJsselmuiden, A. J., Elias, J., van Dongen, I. M., Tijssen, R., Koch, K. T., Baan, J., Jr, Vis, M. M., de Winter, R. J., Piek, J. J., Tijssen, J., Henriques, J., & AIDA Investigators (2017). Bioresorbable Scaffolds versus Metallic Stents in Routine PCI. The New England Journal Of Medicine, 376(24), 2319–2328.
Yano, H., Horinaka, S., Watahiki, M., Watanabe, T., & Ishimitsu, T. (2019). Five-year outcomes after first- and second-generation drug-eluting stent implantation in all patients undergoing percutaneous coronary intervention. Journal Of Cardiology, 74(2), 169–174.
Zhang, H., Wang, X., Deng, W., Wang, S., Ge, J., & Toft, E. (2016). Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine, 95(38), e4820.
Zhu, P., Zhou, X., Zhang, C., Li, H., Zhang, Z., & Song, Z. (2018). Safety and efficacy of ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer drug-eluting stents: a meta-analysis of randomized trials. BMC Cardiovascular Disorders, 18(1), 170.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Bruno Wesley Ramalho Cirilo Ferreira, Anais Bezerra de Gusmão, Luara de Sousa Monteiro Duarte, Milena Bezerra Coutinho, Kalino Grangeiro Wanderley, Cibério Landim Macedo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
